Michael Dworzak, MD, PhD is an expert in Hematology at St Anna Children's Hospital (Austria). As of October 2026, ScienceLeadR ranks Michael Dworzak in the top 1% of experts worldwide for Leukemia. Michael Dworzak has authored 332 publications, the most recent in 2026, and is an investigator in 10 clinical trials. SLR score: 959 (community average: 125). How the SLR is computed.

LeadR Profile

Michael Dworzak, MD, PhD St Anna Children's Hospital Austria
959 ScienceLeadR Reputation 959
Network Map

Hematology

Subspecialties: Oncology - Pediatrics - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1992 - 2026

Source: PubMed

Medical University of Vienna

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 332

Citations

Citations: 14 317 1st author: 16 Last author: 29 Unique author: 5


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Parvovirus B19 infections in paediatric sickle cell disease patients: Genotype and hydroxyurea treatment influence disease severity.
PMID 42732975 — cells, parvovirus b19, human, hematology, anemia, sickle cell, parvovirus, erythema infectiosum, signs and symptoms, genotype, therapeutics, infections, hydroxyurea
Br J Haematol20260
Incidence and Risk Factors of Symptomatic Osteonecrosis in Children With Acute Lymphoblastic Leukemia-A Population-Based Analysis of the Austrian ALL-BFM Study Group.
PMID 42344887 — precursor cell lymphoblastic leukemia-lymphoma, incidence, leukemia, sex, risk factors, osteonecrosis, child
EJHaem20260
Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.
PMID 41558034 — anemia, aplastic, anemia, transplants, hematologic diseases
Blood Adv20260
Concurrent Juvenile Myelomonocytic Leukemia and Gliomas in Patients With Neurofibromatosis Type 1.
PMID 41454800 — leukemia, myelomonocytic, juvenile, glioma, neoplasms, leukemia, neurofibromatosis 1, neurofibromatoses
Pediatr Blood Cancer20250
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.
PMID 41213101 — incidence, mycoses, daunorubicin, anthracyclines, therapeutics, invasive fungal infections, prognosis, infections, child
J Clin Oncol Top journal20251

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 4
Phase 3 2
Phase 1 1
Phase 2 1
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 5
Recruiting 2
Active not recruiting 1
Suspended 1
Unknown 1

By type:

Interventional 7
Observational 3

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 2
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map